Recursion Pharmaceuticals Inc (RXRX)
5.695
-0.06
(-0.96%)
USD |
NASDAQ |
Nov 22, 16:00
5.75
+0.06
(+0.97%)
After-Hours: 20:00
Recursion Pharmaceuticals Enterprise Value: 1.249B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 1.249B |
| November 20, 2024 | 1.332B |
| November 19, 2024 | 1.398B |
| November 18, 2024 | 1.350B |
| November 15, 2024 | 1.371B |
| November 14, 2024 | 1.582B |
| November 13, 2024 | 1.699B |
| November 12, 2024 | 1.774B |
| November 11, 2024 | 1.848B |
| November 08, 2024 | 1.636B |
| November 07, 2024 | 1.588B |
| November 06, 2024 | 1.599B |
| November 05, 2024 | 1.556B |
| November 04, 2024 | 1.504B |
| November 01, 2024 | 1.436B |
| October 31, 2024 | 1.413B |
| October 30, 2024 | 1.513B |
| October 29, 2024 | 1.530B |
| October 28, 2024 | 1.567B |
| October 25, 2024 | 1.455B |
| October 24, 2024 | 1.421B |
| October 23, 2024 | 1.412B |
| October 22, 2024 | 1.493B |
| October 21, 2024 | 1.535B |
| October 18, 2024 | 1.587B |
| Date | Value |
|---|---|
| October 17, 2024 | 1.475B |
| October 16, 2024 | 1.607B |
| October 15, 2024 | 1.510B |
| October 14, 2024 | 1.524B |
| October 11, 2024 | 1.495B |
| October 10, 2024 | 1.369B |
| October 09, 2024 | 1.361B |
| October 08, 2024 | 1.444B |
| October 07, 2024 | 1.369B |
| October 04, 2024 | 1.348B |
| October 03, 2024 | 1.334B |
| October 02, 2024 | 1.348B |
| October 01, 2024 | 1.365B |
| September 30, 2024 | 1.485B |
| September 27, 2024 | 1.527B |
| September 26, 2024 | 1.580B |
| September 25, 2024 | 1.501B |
| September 24, 2024 | 1.487B |
| September 23, 2024 | 1.439B |
| September 20, 2024 | 1.476B |
| September 19, 2024 | 1.515B |
| September 18, 2024 | 1.507B |
| September 17, 2024 | 1.465B |
| September 16, 2024 | 1.434B |
| September 13, 2024 | 1.411B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
276.51M
Minimum
May 11 2022
6.341B
Maximum
Jul 13 2021
1.828B
Average
1.475B
Median
Oct 17 2024
Enterprise Value Benchmarks
| Revance Therapeutics Inc | 649.94M |
| NovaBay Pharmaceuticals Inc | 2.798M |
| Palatin Technologies Inc | 15.96M |
| iBio Inc | 12.31M |
| Theriva Biologics Inc | -12.68M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -95.84M |
| Revenue (Quarterly) | 26.08M |
| Total Expenses (Quarterly) | 124.44M |
| EPS Diluted (Quarterly) | -0.34 |
| Gross Profit Margin (Quarterly) | 53.69% |
| Profit Margin (Quarterly) | -367.5% |
| Earnings Yield | -27.22% |
| Normalized Earnings Yield | -27.22 |